Hemogenyx Pharmaceuticals Plc

SILF

GB00BYX3WZ24

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 09:05:12 31/05/2024 pm IST			5-day change	1st Jan Change
1.475 ^GBX	-1.07%		0.00%	-35.87%

25/04	EARNINGS: LSL starts 2024 "strongly"; Focusrite maintains payout	AN
25/04	Hemogenyx Pharmaceuticals Plc Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Robin Campbell to Step Down as Non-Executive Director of Hemogenyx Pharmaceuticals Plc, Effective January 5, 2019

December 20, 2018 at 12:30 pm IST

Hemogenyx Pharmaceuticals plc announced that Robin Campbell, Non-Executive Director, will step down from the Board with effect from 5 January 2019.

Latest news about Hemogenyx Pharmaceuticals Plc

EARNINGS: LSL starts 2024 "strongly"; Focusrite maintains payout	25/04	AN
Hemogenyx Pharmaceuticals Plc Reports Earnings Results for the Full Year Ended December 31, 2023	25/04	CI
Hemogenyx Pharmaceuticals raises money for leukaemia treatment	29/02	AN
Hemogenyx Pharmaceuticals Raises $4.2 Million via Share Placing	29/02	MT
Hemogenyx Pharmaceuticals Achieves Breakthrough in Brain Cancer Treatment	16/02	MT
Hemogenyx shares rise on potential for CBR to treat brain diseases	16/02	AN
Hemogenyx Pharmaceuticals plc Announces CBR Brain Delivery	16/02	CI
Hemogenyx Pharmaceuticals Tests Intranasal Delivery for Viral Infections Treatment	14/02	MT
Hemogenyx says CBR can be used intranasally to treat viral infections	14/02	AN
Hemogenyx shares surge as FDA lifts Hemo-Car-T trial hold	09/02	AN
US FDA Removes Clinical Hold on Hemogenyx Pharmaceuticals' Acute Myeloid Leukemia Treatment	09/02	MT
Hemogenyx Pharmaceuticals PLC Announces FDA Consents to Phase I Trials of HEMO-CAR-T	09/02	CI
Hemogenyx Pharmaceuticals Obtains US Conditioning Patent	02/02	MT
Hemogenyx hails US patent application progress	02/02	AN
Hemogenyx Pharmaceuticals plc Announces Approval and Issuance of U.S. Conditioning Patent	02/02	CI
Hemogenyx Pharmaceuticals sends complete response on HEMO-CAR-T to FDA	16/01	AN
Hemogenyx Files Complete Response to US FDA's Clinical Hold of Leukemia Treatment Application	16/01	MT
Hemogenyx Pharmaceuticals completes process qualification run	08/01	AN
Hemogenyx Pharmaceuticals Wraps Up HEMO-CAR-T Process Qualification Run Following Clinical Hold	08/01	MT
Hemogenyx Pharmaceuticals plc Announces Successful Completion of Its Process Qualification Run of the End-To-End Process for the Manufacture of HEMO-CAR-T Cells	08/01	CI
Upland Resources completes technical study at Sarawak	28/11	AN
Hemogenyx Platform Shows Potential for Blood Cancer Treatment; Shares Climb	27/11	MT
Hemogenyx shares up as says CBR platform a potential cancer treatment	27/11	AN
Hemogenyx Pharmaceuticals plc Announces CBR Expanded to Treatment of Cancer	27/11	CI
Hemogenyx Pharmaceuticals completes lentivirus re-manufacture	15/11	AN

Chart Hemogenyx Pharmaceuticals Plc

Duration

Period

More charts

Hemogenyx Pharmaceuticals plc is a preclinical-stage biotechnology company. The Company is focused on the discovery, development and commercialization of treatments relating to bone marrow/hematopoietic (blood-forming) stem cell (BM/HSC) transplants for blood diseases, including leukemia, lymphoma and bone marrow failure and viral infections. It is developing several distinct and complementary product candidates, as well as a platform technology. To obviate the use of chemotherapeutic agents for conditioning of patients undergoing BM/HSC transplantations, the Company developed a method of selective elimination of hematopoietic stem cells/hematopoietic progenitors (HSC/HP) in patients using highly specific CDX antibodies. It has developed postnatal human hemogenic endothelial cells (Hu-PHEC cells) to generate cancer-free hematopoietic stem cells (HSC) for use in transplants to treat blood cancers. It has developed HEMO-CAR-T, for the potential treatment of acute myeloid leukemia (AML).

Sector

Biotechnology & Medical Research

Calendar

26/09/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
HEMOGENYX PHARMACEUTICALS PLC	-35.87%	2.55Cr
VERTEX PHARMACEUTICALS INCORPORATED	+10.64%	11TCr
REGENERON PHARMACEUTICALS, INC.	+10.32%	10TCr
BIONTECH SE	-4.80%	2.38TCr
ARGENX SE	-0.82%	2.17TCr
GENMAB A/S	-10.12%	1.81TCr
WUXI APPTEC CO., LTD.	-42.12%	1.63TCr
BEIGENE, LTD.	-17.03%	1.61TCr
NEUROCRINE BIOSCIENCES, INC.	+2.64%	1.38TCr
SAREPTA THERAPEUTICS, INC.	+32.27%	1.18TCr